STOCK TITAN

Instil Bio, Inc. - $TIL STOCK NEWS

Welcome to our dedicated page for Instil Bio news (Ticker: $TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Instil Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Instil Bio's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.09%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.7%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.02%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
none
Instil Bio, Inc.

Nasdaq:TIL

TIL Rankings

TIL Stock Data

76.75M
3.06M
6.84%
65.92%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
DALLAS

About TIL

instil bio is a cell therapy company developing tumor infiltrating lymphocytes (til) for the treatment of solid tumor cancers. til are a patient’s own t cells harvested from the patient’s tumor, which are then expanded and reinfused into the patient to target and kill cancer cells. the company is advancing its proprietary manufacturing expertise, technology, and data into clinical trials, including a planned registrational study with its lead candidate and a first-in-human study of its next-generation engineered til. the company is led by world-class cell therapy experts and backed by premier global institutional investors. instil is located in the greater los angeles area with additional manufacturing and research facilities in manchester, uk.